Optimist. Prof GI medical oncology. Coffee, Irn-Bru & dog enthusiast @foxtrotstudy @focus4trial @ArielTrial #pelotonuk 🇪🇺
Edinburgh born, Leeds based
Joined October 2014
- Tweets970
- Following735
- Followers1.3K
- Likes4K
Pinned Tweet
Thanks for all the positive messages re FOCUS4C. Beyond delighted to see this in @guardian theguardian.com/society/2021…
Jenny Seligmann retweeted
👏👏👏
FOxTROT 5 testing peri-op dostarlimab in MSI-H locally advanced colon cancer in older or frail patients. Thanks to our fantastic 🇬🇧 investigators.
FOxTROT 6 to follow soon….
@yorkshirecancer @adbeggs @JenSeligmann @LTHTResearch
Jenny Seligmann retweeted
Jordan Appleyard Presents HER3 Analysis from FOxTROT Trial at ASCO GI - @JenSeligmann
oncodaily.com/voices/jenny-s…
#Cancer #ASCOGI26 #OncoDaily #Oncology #MedEd #MedTwitter #MedX #MedOnc @CancerWorldmag
Jenny Seligmann retweeted
🆕Article of the Month podcast🎧: @tompowles1 discusses the FOxTROT trial in locally advanced colon cancer with @JenSeligmann
tinyurl.com/2sv3eyf4
For the full study report see:
doi.org/10.1016/j.annonc.202…
Jenny Seligmann retweeted
#ESMO25 @myESMO
A pleasure to join this symposium with @JenSeligmann & Julien Taieb
➡️ more choices in refractory mCRC ✅
➡️ needs a tailored approach to optimize tx
@TakedaOncology
@myESMO
#ESMOAmbassador
Neoadjuvant IO for locally advanced MSS colon ca….
This article helps us take a further step forward by demonstrating clear efficacy and signals towards biomarkers for pt selection.
💥💥huge congrats to my team neoadjuvant dear friend and team!
We will get there in colon cancer
Very proud and happy to share that our work on neoadjuvant IO in pMMR colon cancers has been published online in @Nature after presentation @myESMO #ESMO25. Preview: rdcu.be/eLTN1 Read on how genomic instability, P53mt and proliferation may aid in predicting responses.
Proud to present combined NICHE-2 & FOXTROT analysis in dMMR locally advanced CC
-Neoadjuvant IO superior to chemo
-20% relapses with chemo in "good prognosis" group; 30% if T4
-Minimal path response to chemo
- Clinical staging identified high risk group
My take homes....
Further support of neoadjuvant IO esp for high risk pts
Chemo no or limited role for dMMR early CC (?ATOMIC strategy)
Clinical staging CAN identify high risk pts
20% recurrence relevant when effective rx available!
@MyriamChalabi @CRUKresearch @oncodaily
Thanks for highlighting!! @MyriamChalabi
NICHE-2 absolutely delivers. Game over for chemo in dMMR colon cancer 💥🧬
In locally advanced dMMR colon cancer, FOxTROT already showed us chemo doesn’t work, and now NICHE-2 makes it undeniable.
💊 Neoadjuvant nivolumab + ipilimumab →
• 99% pathologic response
• 67% pathologic CR
• Zero recurrences to date at 3 years
🪦 This is the final coffin nail for perioperative chemotherapy in this setting. ATOMIC is already on life support despite being published less than a year ago.
The real question now: with Cercek’s rectal data, can we safely omit surgery next?
At minimum, this should be the new standard.
At maximum, it’s the start of a paradigm shift.
@OncoAlert @TheGutOncLab #ESMO25
Jenny Seligmann retweeted
Durvalumab & tremelimumab + local partial tumour ablation in pts with unresectable liver mts from mCRC: results of the EORTC-1560-GITCG ph II study (ILOC) in @ESMO_Open. No benefit with ICIs combination in this pts group with high therapeutic unmet need. esmoopen.com/article/S2059-7…
🎆 Now online - my 2 fav topics in one paper
👍FOxTROT Ph2 FOLFOX+/- pani in locally advanced RAS/RAF-wt colon cancer
👍Convincing activity of anti-EGFR on long term outcomes, esp in hyperselected pts
❓Time to re-think targeted agents in LACC/LARC
annalsofoncology.org/article…
🤔Pani had little effect on path response
👍Prospective trial in LACC RAS/RAF-wt EREG/AREG pts planned
❓Consider in LARC
This will be my last tweet - hope to see you on Bluesky 👋
@b
Jenny Seligmann retweeted
Just finished. Very interesting #MiniOral #ESMOAsia24 session in #PDAC and #Biliary that I had the pleasure to co-chair (and discuss) with @JenSeligmann
Posts coming with my thoughts 😉
Thanks @LorenzaRimassa for the 📸
🫶
@myESMO
The mini oral session on #GI cancer continues at #ESMOAsia24 in #Singapore. More abstracts on gastric, gastroesophageal, and GEJ cancer, but also on #BTC and #PDAC @myESMO @DrAngelaLamarca @JenSeligmann
Jenny Seligmann retweeted
Check out our editorial on high-risk stage II colon cancer: a call for clinicians to exercise caution when withdrawing oxaliplatin and when interpreting subanalyses
sciencedirect.com/science/ar…
@DrClaireGallois @JenSeligmann
Epic @chrisjmwilliams leading this 👍🏻
Very timely review post #ESMO24 neoadjuvant colon IO data!
Delighted to be involved plus international 🤝
@NatRevClinOncol @OncoAlert @LIMRLeeds
This Post is from an account that no longer exists. Learn more
Neoadjuvant immunotherapy for msi-h colon and rectal cancer 👍🏻
But emerging data on complications not seen with chemo
Project initiated after a pt developed bowel obstruction due to stricturing response to IO
➡️emergency resection
➡️pCR
👏@Jplatt_19 & our international 🤝
Delighted to have this published. Fantastic effort from all involved!
✅ ICIs transforming Tx of dMMR CRC
✅ Common toxicities now well recognised but...
💥 Is bowel obstruction a rare complication when primary tumour in situ?!
International case series in @ESMO_Open ⬇️⬇️⬇️
Tumour immune markers absolutely relevant in risk stratification for early stage colon cancer ✅
Great collaboration with @RocheDiaUSA @UniversityLeeds
👏👏@chrisjmwilliams published in
@JCO_ASCO 🤩
This Post is from an account that no longer exists. Learn more
Plus a mystery LBA in this session…🤩 💥💥💥
Can’t wait #ESMO24
Abstract titles for #ESMO24 now online! Full NICHE-3 cohort (59 pts with dMMR colon cancer treated with neoadj nivo/rela) will be presented in proferred paper session + more neoadj IO from Imhotep, and wonderful @JenSeligmann as discussant. Stay tuned for more exciting💥💥💥news!
Jenny Seligmann retweeted
How to integrate NACT in locally advanced colon cancer:
👉 enroll pts in clinical trials
👉 gain experience
👉 MDT is crucial
@JenSeligmann
#ESMOGI24 @myESMO
🙏🏽🙏🏽@ChiaraCrem1
That’s a wrap for day 1 of #ESMOGI24
Privilege to share the stage with @JeanneTie to discuss advances in localised colon cancer
@FoxtrotStudy @DucreuxMichel
Outstanding presentation by @JenSeligmann at #ESMOGI24 about neoadj strategies to modify the status quo in localized colon cancer. Academic research will be the key, sure! 💪🏻 @myESMO #ESMOAmbassadors
